Skip Navigation

AIDSInfo-at-a-glance

Issue No. 46 | November 05, 2010
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

HHS Perinatal Guidelines Panel Accepting Nominations for New Members

The Department of Health and Human Services (HHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission in the United States (the Perinatal Guidelines Panel) is accepting nominations for new members with clinical research and/or practice expertise in HIV in women and prevention of mother-to-child transmission (PMTCT) of HIV. Ideal candidates will have a background in women’s health, including obstetrics/gynecology, internal medicine, or nursing, and recognized expertise in PMTCT and the management of HIV-infected women as evidenced by, for example, participation in clinical research and meaningful contributions to peer review journals.

The Perinatal Guidelines Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is composed of approximately 25 members including clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV infection in pregnant women and interventions for PMTCT. The Panel meets monthly via teleconference (and occasionally in person) to evaluate emerging scientific data and to prepare revisions to the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. The latest guidelines were released on May 24, 2010, and are available at the AIDSinfo Web site.

Panel members serve a 3-year term with an option for membership renewal. Panel members are not compensated for their time commitment, and travel support is not provided for participation.

The nomination should include a curriculum vitae and a letter of nomination or letter of interest outlining what qualities and contributions the candidate may bring to the Panel. Submit nominations no later than December 15, 2010, to Lynne M. Mofenson, M.D., Panel Executive Secretary, at LM65D@nih.gov or Lynne.Mofenson@nih.hhs.gov or to the National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Blvd, Room 4B11, Rockville, MD 20852; Fax: 301-496-8678.

NIH Study Suggests Ritonavir-Boosted Lopinavir Regimen is Superior to Nevirapine Regimen in HIV-Infected Infants

“A recent scheduled interim data and safety review of a clinical study comparing anti-HIV treatment regimens in young children who acquired HIV during birth or breastfeeding has found a lopinavir (LPV/r)-based regimen more effective than a nevirapine (NVP)-based regimen in children who were not previously exposed to NVP.  Consequently, the study team has unblinded the data and has advised the parents and guardians of the children to consult with their healthcare providers about the best antiretroviral regimen for their children. …

“In 2009, an interim review of the study data showed that the [LPV]/r-based regimen was more effective than the NVP-based regimen in children previously exposed to single-dose nevirapine. As a consequence, cohort 1 was closed to accrual in 2009 and the initial findings published in the Oct. 14, 2010 issue of the New England Journal of Medicine. Now the study has determined that the LPV/r-based treatment regimen also is more effective than the NVP-based regimen in children who lack previous exposure to single-dose NVP. …

“The strength of these data led the DSMB to recommend that the investigators unblind the results and share them as soon as possible with the scientific community, study investigators and the parents and guardians of the participating children.”

More information is available:

AIDSinfo Releases HIV/AIDS Glossary iPhone Application!

AIDSinfo is pleased to announce the release of its first iPhone application, the AIDSinfo HIV/AIDS Glossary App! This follows the release of the mobile AIDSinfo site and marks our commitment to providing users with federally approved HIV/AIDS information optimized for mobile devices. The glossary application, along with all future AIDSinfo applications, will eventually be offered across several mobile platforms, including BlackBerry and Android-enabled phones.

The AIDSinfo HIV/AIDS Glossary application, designed specifically for iPhones, provides on-the-go access to the same HIV/AIDS terms found in the AIDSinfo Glossary of HIV/AIDS-Related Terms. The application includes the following features:

  • More than 850 HIV/AIDS-related terms clearly defined in both English and Spanish
  • Toggle button to switch between the English and Spanish term and definition, allowing the application to function as a translation tool
  • Multiple ways to search for terms

AIDSinfo welcomes feedback about the new glossary application. Please send comments or questions to ContactUs@aidsinfo.nih.gov.

More information is available:

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image